Fortress Biotech, Inc. (CNB0)

Overview

Fortress Biotech, Inc. is a leading biopharmaceutical company based in Bay Harbor Islands, Florida, specializing in the development of innovative dermatology and pharmaceutical and biotechnology products primarily for the U.S. market. The company's business strategy involves marketing approved dermatological products while also advancing a diverse pipeline of late-stage and early-stage product candidates targeting various medical conditions and diseases. Formally known as Coronado Biosciences, Inc., the company underwent a rebranding to Fortress Biotech, Inc. in April 2015. Since its inception in 2006, Fortress Biotech has established multiple collaboration arrangements with universities, research institutes, and pharmaceutical companies, underlining its commitment to combatting serious health issues through advanced biotechnological research and development.

Products and Services

Marketed Dermatology Products:

• Qbrexza: A medicated cloth towelette designed for the treatment of primary axillary hyperhidrosis, commonly known as excessive underarm sweating.
• Accutane Capsules: Prescribed for severe recalcitrant nodular acne, these capsules represent a potent therapy for those unresponsive to conventional treatments.
• Amzeeq: A topical formulation for severe acne vulgaris, offering a novel therapeutic approach to manage this widespread skin condition.
• Zilxi: A topical foam indicated for various dermatological uses.
• Exelderm Cream: A cream for topical application aimed at treating specific dermatological conditions.
• Targadox: An oral doxycycline drug that serves as adjunctive therapy for severe acne, highlighting the company's focus on acne treatments.
• Luxamend: A wound care cream, showcasing Fortress Biotech's entry into therapeutic wound management.

Development Pipeline:

• Intravenous Tramadol: In late-stage development for post-operative acute pain management.
• CUTX-101: An injection under development for treating Menkes disease, a genetic disorder affecting copper levels in the body.
• Cosibelimab: A late-stage candidate for the treatment of metastatic cancers, representing the company's foray into oncology.
• Olafertinib: Targeting patients with EGFR mutation-positive NSCLC, highlighting the company's commitment to precision medicine in lung cancer.
• CAEL-101: Designed for treating amyloid light chain amyloidosis, a rare disease characterized by the deposition of amyloid in organs.
• Triplex vaccine: A vaccine for cytomegalovirus to prevent infection, especially in immunocompromised individuals.
• DFD-29: Under development for rosacea, offering a new therapeutic option for those suffering from this chronic skin condition.

Early Stage and Preclinical Candidates: The company’s early-stage and preclinical product candidate portfolio include novel therapies for gout (Dotinurad), B-cell non-Hodgkin lymphoma (MB-106), glioblastoma (MB-101, MB-108, MB-109), and several other diseases, demonstrating Fortress Biotech’s broad research and development efforts across various areas of high unmet medical need.